Ying Xu

机构：Howard Hughes Medical Institute, Shandong University of Traditional Chinese Medicine, North China University of Science and Technology, Guizhou University, University of California, San Francisco, North China University of Science and Technology Affiliated Hospital · ORCID：0000-0001-9994-9889

发表论文 252 篇 · 总被引 4903 次 · h-index 30

代表论文

• A Novel RANKL/RANK Inhibitor IMB-R38 Inhibits Osteoporosis Through Regulating Bone Metabolism (2025 · International Journal of Molecular Sciences · 被引 3)
• Surgical treatment of giant phyllodes tumors of the breast: a series of rare cases (2025 · Frontiers in Oncology · 被引 3)
• Phenotypic pleiotropy of missense variants in human B cell confinement receptor P2RY8 (2025 · Cell Genomics · 被引 3)
• Discovery of a macrocyclic FAK inhibitor GZD-257 for treatment of glioblastoma (2025 · Bioorganic & Medicinal Chemistry Letters · 被引 2)
• First-in-human study of DGPR1008 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer in patients undergoing radical prostatectomy (2025 · Translational Andrology and Urology · 被引 2)
• Design, synthesis, and anti-glioblastoma multiforme evaluation of novel multikinase inhibitors via a cyclization strategy with potent FAK inhibition (2026 · European Journal of Medicinal Chemistry · 被引 1)